Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Remarkably Stable Virus-Like Positive Controls for COVID-19 Assays

By LabMedica International staff writers
Posted on 09 Dec 2020
Researchers have prepared a new class of positive control materials to validate the molecular assays that have been developed to detect and diagnose COVID-19 infection.

Nucleic acid tests, especially reverse transcription polymerase chain reaction (RT-PCR), have become the standards for early detection of COVID-19 infection. More...
Positive controls for the molecular assays have been developed to validate each test and to provide high accuracy. However, most available positive controls require cold-chain distribution and cannot serve as full-process controls.

To overcome these shortcomings, investigators at the University of California, San Diego (USA) have developed new and improved positive controls. The investigators developed two different controls: one made from plant virus nanoparticles, the other from bacteriophage nanoparticles.

The plant virus-based controls were made using cowpea chlorotic mottle virus. The investigators removed the RNA contents of the virus and replaced them with a synthesized RNA template containing specific sequences from the SARS-CoV-2 virus.

Plasmids (segments of circular DNA) were used to make the bacteriophage-based controls. Plasmids containing gene sequences from the SARS-CoV-2 virus, as well as genes coding for surface proteins of the bacteriophage Qbeta, were loaded into bacteria. The bacteria then generated virus-like particles with SARS-CoV-2 RNA sequences on the inside and Qbeta bacteriophage proteins on the outside.

Results revealed that the positive control materials were detected accurately in COVID-19 molecular assays. The controls were stable and could be stored for a week at temperatures up to 40 degrees Celsius while retaining 70% of their activity after one month of storage.

"Our goal is to make an impact not necessarily in the hospital, where you have state-of-the-art facilities, but in low-resource, under served areas that may not have the sophisticated infrastructure or trained personnel," said senior author Dr. Nicole Steinmetz, professor of nanoengineering at the University of California, San Diego. "It is a relatively simple nanotechnology approach to make low-tech assays more accurate. "This could help break down some of the barriers to mass testing of under served populations in the United States and across the world."

The new COVID-19 positive controls were described in the November 25, 2020, online edition of the journal ACS Nano.

Related Links:
University of California San Diego


Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated MALDI-TOF MS System
EXS 3000
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.